Skip to content
  • Home
  • Subscribe to email list

Pharminent

  • Home
  • Subscribe to email list
Arthritis May 23, 2017June 4, 2017

Sanofi and Regeneron score FDA approval for arthritis

The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis (RA) in patients who have not responded to prior therapy.   
read more http://www.pharmafile.com/news/514154/sanofi-and-regeneron-score-fda-approval-arthritis

Post navigation

← Previous Post

FDA clears Merck’s Keytruda for cancer patients with certain biomarkers

Next Post →

Merck licenses Teijin Pharma’s Alzheimer’s candidate

Categories
RSS Emerging Markets
  • Chinese R&D sector takes ‘significant step’ as outsourcing demand increases December 7, 2017
  • Six factors shaping healthcare in emerging markets October 10, 2017
  • How Startups Are Trying To Overcome India’s Healthcare Challenges September 25, 2017
  • Trovagene Announces Agreement with Novogene for NextCollect™ in China July 12, 2017
  • China FDA changes will speed up approval process, says CRO June 7, 2017
  • India’s drugmakers need more time to meet international standards: industry group May 17, 2017
  • Generic consistency evaluation in China: the coming paradigm shift in drug pricing and patent cliff April 19, 2017
RSS Biosimilar
  • Biogen looking to up its stake in Samsung biosimilar JV February 1, 2018
  • Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars January 18, 2018
  • Lucentis biosimilar: Formycon eyes 2020 for US launch November 28, 2017
  • Five more biosimilar-free years for AbbVie’s Humira September 28, 2017
  • Boehringer’s Humira biosimilar wins US green light August 30, 2017
  • Second US infliximab biosimilar launched at 35% discount to J&J’s Remicade July 25, 2017
  • Biosimilar immunogenicity studies produce no surprises June 26, 2017
RSS Pricing
  • Roche hemophilia drug lowers costs despite high price: ICER January 27, 2018
  • Payers point to Spark’s gene therapy as a model for innovative pricing plans January 12, 2018
  • FDA eyes even more pricing competition with another round of generics moves November 14, 2017
  • New Infographic: A Response to “A Better Deal” on Drug Pricing September 21, 2017
  • On Drug Pricing: FDA Backs Up Its Calls for Increased Competition August 21, 2017
  • Perspectives: More Transparent Pricing System Would Help Untangle Confusion Around High Costs July 12, 2017
  • EU tests limits of drug pricing freedom in landmark probe June 26, 2017
RSS Payer
  • CMS Considers Alternate Payment Models To Curb Costs On High-Price Treatments, Gene Therapy December 1, 2017
  • Novartis’ CAR-T drug needs new payment model, says Express Scripts September 25, 2017
  • Op-Ed: Why single-payer health-care could be closer than you think June 26, 2017
  • CVS Point-Of-Sale Rebate Program Adopted By ‘Several’ Payers June 15, 2017
  • CMS Press Releases Take on a More Political Tone May 16, 2017
RSS Marketing
  • AstraZeneca at Cannes: Healthcare delivery’s speeding away from pharma’s marketing model June 26, 2017
  • What marketers need to know about tax reform, off-label promotion, pricing May 17, 2017
  • The Impact of AI and Machine Learning in Marketing February 27, 2017
RSS R&D
  • Novartis and Apple to scale up clinical trial collaboration January 24, 2018
  • The rise of wearable technology for clinical trials: insights from Novartis November 27, 2017
  • Propeller Health Expands Digital Health R&D Partnership with GSK August 28, 2017
RSS Company News
  • France’s Sanofi buys US hemophilia specialist Bioverativ January 22, 2018
  • Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance January 7, 2018
  • Amazon in Exploratory Talks With Mylan, Novartis About Pharma Entry December 1, 2017
  • Novartis moves closer to spinning off Alcon eyecare division October 24, 2017
  • J&J, Roche among companies selected for FDA digital health pilot September 27, 2017
  • Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines September 20, 2017
  • Bristol, Roche tap Halozyme for tech platform September 14, 2017
RSS Immunotherapy
  • ASH 2017: CAR-T therapy and beyond December 6, 2017
  • 4 Ways To Market CAR-T Therapies October 16, 2017
  • AstraZeneca, NewLink pen PD-L1 and IDO combination pact September 25, 2017
  • Gilead aims to expand CAR-T manufacturing capabilities post-Kite acquisition September 2, 2017
  • Real world data essential for CAR-T therapy success August 14, 2017
  • Kite files first CAR-T candidate in Europe August 1, 2017
  • FDA panel backs Novartis’ CAR-T therapy CTL019 July 13, 2017
RSS Cardiovascular
  • Amgen gets prevention claim for cholesterol drug Repatha December 4, 2017
  • AstraZeneca outlicenses Brilinta reversal agent November 28, 2017
  • EU OKs low-dose Xarelto to prevent recurrent VTE November 2, 2017
  • AstraZeneca touts Brilinta CV benefit with new analysis August 24, 2017
  • Merck, Novartis pipeline stunners headline surprisingly good month for CV agents June 28, 2017
  • Novartis heart drug success opens up new care option June 22, 2017
  • Oral anticoagulants still underutilized in AFib: study June 7, 2017
RSS Diabetes
  • Boehringer strikes Jardiance outcomes deal with Prime PBM January 31, 2018
  • Lilly partners with Rimidi on digital diabetes management tool December 15, 2017
  • One Drop and Fitbit to integrate diabetes and activity data November 1, 2017
  • Fitbit and Dexcom to bring diabetes data to Ionic smartwatch September 8, 2017
  • Diabetes drugmakers partner with mobile startups to boost patient engagement July 20, 2017
  • Roche acquires mySugr to form a leading open platform for digital diabetes management June 30, 2017
  • Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial June 23, 2017
RSS Alzheimer’s
  • AbbVie, Alector to develop novel treatments for Alzheimer’s disease October 25, 2017
  • Assessing The Pipeline For Alzheimer’s Disease (Part I: Anti-Amyloid Antibodies) October 13, 2017
  • Biogen’s Alzheimer’s Hope Tops The Sector’s Most Valuable Pipeline Projects August 16, 2017
  • New Gene Discoveries Could Redefine Alzheimer’s Treatment July 21, 2017
  • 5 trends shaping Alzheimer’s drug development July 17, 2017
Create a website or blog at WordPress.com